Development, validation and application of a novel HPLC-MS/MS method for the quantification of atorvastatin, bisoprolol and clopidogrel in a large cardiovascular patient cohort by Turner, Richard Myles et al.
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Cardiovascular  disease  is  a leading  cause  of  morbidity,  mortality,  and  healthcare  expenditure  world-
wide.  Importantly,  there  is interindividual  variation  in  response  to cardiovascular  medications,  leading
to variable  efﬁcacy  and  adverse  events.  Therefore  a rapid,  selective,  sensitive  and  reproducible  multi-
analyte  HPLC-MS/MS  assay  for the quantiﬁcation  in  human  plasma  of  atorvastatin,  its  major  metabolites
2-hydroxyatorvastatin,  atorvastatin  lactone  and  2-hydroxyatorvastatin  lactone,  plus  bisoprolol  and
clopidogrel-carboxylic  acid has  been  developed,  fully  validated,  and  applied  to  a large  patient  study.  Fifty
microliter  plasma  samples  were  extracted  with  a simple  protein  precipitation  procedure  involving  ace-
tonitrile  with  acetic  acid  (0.1%,  v/v).  Chromatographic  separation  was  via  a 2.7  m  Halo  C18  (50  × 2.1 mm
ID,  90  Å) column  and  gradient  elution  at a ﬂow  rate of 500  L/min  consisting  of  a  mobile  phase  of  water
(A)  and  acetonitrile  (B), each  containing  0.1%  formic  acid  (v/v),  over  a 6.0  min  run  time.  The  six  analytes
and  their  corresponding  six deuterated  internal  standards  underwent  positive  ion  electrospray  ionisa-
tion  and  were  detected  with  multiple  reaction  monitoring.  The  developed  method  was  fully  validated
with  acceptable  selectivity,  carryover,  dilution  integrity,  and within-run  and  between-run  accuracy  and
precision.  Mean  extraction  recovery  for the  analytes  was  92.7–108.5%,  and  internal  standard-normalised
matrix  effects  had  acceptable  precision  (coefﬁcients  of  variation  2.2–12.3%).  Moreover,  all  analytes  were
stable  under  the tested  conditions.  Atorvastatin  lactone  to acid  interconversion  was  assessed  and  recom-
mendations  for  its minimisation  are  made.  The  validated  assay  was successfully  applied  to  analyse  1279
samples  from  1024  patients  recruited  to a  cardiovascular  secondary  prevention  prospective  study.
© 2018  Published  by  Elsevier  B.V.. Introduction
Cardiovascular disease (CVD) is a leading cause of morbid-
ty and is responsible for ∼27% of all deaths worldwide [1]. The
athogenesis of CVD is complex and multifaceted [2,3]. Differ-
nt drug classes are therefore frequently prescribed together for
he secondary prevention of CVD, including: 3-hydroxy-3-methyl-
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731-7085/© 2018 Published by Elsevier B.V.glutaryl-coenzyme A reductase (HMGCR) inhibitors (statins, e.g.
atorvastatin (ATV)), beta-adrenergic receptor antagonists (beta
blockers, e.g. bisoprolol (BSP)) and antiplatelet drugs (e.g. clopido-
grel (CLP)). It is axiomatic that drug effectiveness and toxicity are
related to systemic drug concentrations to a certain extent, which
can vary between individuals due to clinical (e.g. age, comorbidi-
ties), environmental (e.g. drug-drug and drug-food interactions)
and genetic factors [4]. Therefore, there is a need to develop
straightforward quantitative multi-drug assays and apply them to
large patient cohorts to further parse the pharmacokinetic determi-
nants of cardiovascular drug exposure, to determine the strengths
of association between dose, exposure and outcome, and to poten-
tially guide cardiovascular dosing in prospective studies and future
clinical care.
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Fig. 1. Chemical structures and relevant metabolism of analytes.
Abbreviations: CES1 = carboxylesterase 1; CYP = cytochrome P450; UGTs = uridine 5’-diphospho-glucuronosyltransferases. The red rings denote the analytes quantiﬁed in
this  assay: parent ATV, its major hydroxylated metabolite (2-OH ATV), their corresponding lactones (ATV L and 2-OH ATV L), BSP, and the major CLP metabolite, CLP–CA. A:
ATV  and its hydroxylated acid metabolites, 2-OH ATV and 4-OH ATV, actively inhibit HMGCR to reduce circulating low-density lipoprotein cholesterol levels, although 2-OH
ATV  is the more abundant active metabolite [6]. The lactone metabolites are produced from the acid forms of ATV by UGTs, do not inhibit HMGCR, but are implicated in
statin-induced muscle toxicity [11–13]. B: BSP is a cardioselective beta-1 adrenergic receptor antagonist racemate; ∼50% is renally excreted unchanged and ∼50% undergoes
hepatic metabolism into labile or inactive metabolites prior to predominant renal excretion [14,15]. The inactive M1 metabolite of BSP is the most abundant BSP metabolite
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he  readily quantiﬁable inactive circulating metabolite, CLP-CA, which has been cor
18,19].
Most of the available assays of human plasma or serum are lim-
ted to one cardiovascular drug [5,6] or therapeutic class [7,8]. One
ssay has been developed for qualitative detection of 34 cardiovas-
ular drugs [9], and another for detecting 78 cardiovascular drugs,
f which 55 compounds had appropriate accuracy and precision
or quantitative determination [10]. Nevertheless, full validation is
ot undertaken with assays of this size, they do not employ analyte-tors, but is highly labile. Nevertheless, ∼85% of administered CLP is metabolised to
d with platelet inhibition indices [18], CLP non-adherence and variable metabolism
speciﬁc deuterated internal standards (ISs) and extraction requires
a potentially time consuming evaporation stage. Importantly, these
assays have only been applied to modest numbers of samples from
patients - for example 294 [9] and 13 [10].
The aim of this paper is to describe a newly developed, sensi-
tive, precise, accurate and reproducible high performance liquid
chromatography tandem mass spectrometry (HPLC-MS/MS) assay
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Table 1
MRM  parameters.
Chemical MRM  transition
(Q1->Q3) (m/z)
Declustering
potential (DP,V)
Collision energy
(CE,V)
Collision cell exit
potential (CXP,V)
Acquisition time
(min)
ATV 559.3 → 440.3 116 31 32 3.57
ATV-d5 564.1 → 445.1 46 29 38 3.57
2-OH  ATV 575.3 → 250.2 111 57 50 3.48
2-OH  ATV-d5 580.2 → 255.1 51 57 16 3.48
ATV  L 541.3 → 276.2 50 55 24 3.77
ATV-d5 L 546.3 → 281.2 70 57 25 3.76
2-OH  ATV L 557.3 → 276.2 60 57 24 3.66
2-OH  ATV-d5 L 562.2 → 281.1 70 48 25 3.66
BSP  326.2 → 116.2 96 25 8 2.33
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CBSP-d5 331.0 → 121.1 96 
CLP-CA 308.0 → 198.1 62 
CLP-d4 CA 312.2 → 202.0 41 
or the simultaneous quantiﬁcation of ATV, BSP and CLP analytes
n human plasma, and to apply this assay to one of the largest
parse pharmacokinetic studies reported to date. The assay iden-
iﬁes and quantiﬁes six clinically relevant analytes from the three
echanistically distinct drugs: ATV, 2-hydroxy (2-OH) ATV, ATV
actone (ATV L), 2-OH ATV L, BSP, and CLP-carboxylic acid (CLP-CA)
Fig. 1). Brieﬂy, ATV and its major hydroxylated acid metabolite, 2-
H ATV, actively inhibit HMGCR and lower circulating low-density
ipoprotein cholesterol [6], whilst statin lactone metabolites are
mplicated in statin-induced muscle toxicity [11–13]. BSP is a
ardioselective beta-1 adrenergic receptor antagonist adminis-
ered as a racemate. Approximately 50% of BSP is renally excreted
nchanged and ∼50% undergoes hepatic metabolism into labile
r inactive metabolites that are excreted mainly through the kid-
eys, with the M1  metabolite being the most abundant in human
rine [14,15]. CLP is an antiplatelet prodrug. Approximately 15% is
apidly metabolised to a highly unstable active 5-thiol metabolite
hat requires addition of a preservative immediately after blood
ollection for stabilisation [16,17], which precludes its accurate
uantiﬁcation in routinely collected samples. However, ∼85% of
dministered CLP is metabolised to the readily quantiﬁable inac-
ive circulating metabolite, CLP-CA, which has been correlated with
latelet inhibition indices [18], CLP non-adherence and variable
etabolism [18,19].
. Materials and methods
.1. Chemicals and reagents
The following chemicals were purchased from Toronto Research
hemicals (Toronto, Canada): ATV calcium, 2-OH ATV calcium, ATV
, 2-OH ATV L, BSP hemifumarate, CLP-CA hydrochloride, and their
espective deuterated ISs – ATV-d5 sodium, 2-OH ATV-d5 dis-
dium, ATV-d5 L, 2-OH ATV-d5 L, BSP-d5 and CLP-d4 CA. Acetic
cid, dimethyl sulfoxide (DMSO) and formic acid were obtained
rom Sigma-Aldrich (St. Louis, MO,  USA). Acetonitrile, methanol and
ater were obtained from Fisher Scientiﬁc (Loughborough, UK).
ooled gender unﬁltered human healthy volunteer plasma in K3
thylenediaminetetraacetic acid (EDTA) was purchased from Sera
aboratories International (Seralab, West Sussex, UK). Unless stated
therwise, all reagents were HPLC-grade.
.2. Preparation of solutions, standards and quality controls
Stock solutions were prepared by dissolving each chemical sep-
rately in DMSO (ATV, 2-OH ATV, ATV L, 2-OH ATV L, ATV-d5 L, 2-OH
TV-d5 L) or methanol (BSP, CLP-CA, ATV-d5, 2-OH ATV-d5, BSP-d5,
LP-d4 CA) and stored at -20 ◦C. Two sets of working solutions were
repared: a composite set consisting of ATV, 2-OH ATV, BSP and
LP-CA together in 25:75 acetonitrile-water (v/v); and a lactone set23 10 2.33
15 14 2.14
21 18 2.13
of ATV L with 2-OH ATV L in 100% acetonitrile. Both sets of working
solutions consisted of a solution for each calibration standard, and
a separately prepared solution for each quality control (QC), which
were all prepared at 10x the required concentration in individual
glass vials. Ten calibration standards were prepared in blank human
EDTA-plasma for all analytes except ATV L, which required 8 stan-
dards, at the following concentrations: 0.5, 1.0, 1.5, 3.0, 10.0, 25.0,
50.0, 80.0, 100.0 and 125.0 ng/mL for ATV, 2-OH ATV, 2-OH ATV L
and BSP; 1.2, 2.4, 8.0, 20.0, 40.0, 64.0, 80.0 and 100.0 ng/mL for ATV
L and; 15, 30, 45, 90, 300, 750, 1500, 2400, 3000 and 3750 ng/mL
for CLP-CA. The concentrations of the low, medium and high QCs in
blank human EDTA-plasma were: 1.5, 45.0 and 95.0 ng/mL for ATV,
2-OH ATV, 2-OH ATV L and BSP; 3.6, 36.0 and 76.0 for ATV L and;
45, 1350 and 2850 ng/mL for CLP-CA. An intermediate IS working
solution containing all six deuterated ISs in 100% acetonitrile was
prepared from stock and stored at 4 ◦C. On each day of analysis,
an aliquot of the IS intermediate solution was diluted 10x in 25:75
acetonitrile-water to produce the IS working solution (25 ng/mL
for ATV-d5, 2-OH ATV-d5 and BSP-d5; 55 ng/mL for ATV-d5 L, 2-
OH ATV-d5 L; and 750 ng/mL for CLP-d4 CA). All working solutions
were stored at 4 ◦C, and kept on ice during use. Fresh calibration
standards and QCs were prepared on each day of analysis during
both validation and patient sample runs.
2.3. Sample extraction
Fifty microliters of plasma were transferred into a 96-well plate
and 20 L IS working solution was  added. The samples were gen-
tly agitated for 8 min  at 750 rpm (Orbit
TM
P2 digital shaker, Labnet
International, USA) before 180 L of 100% acetonitrile containing
0.3% acetic acid (v/v) was  added for protein precipitation. The plates
were further agitated for 2 min, centrifuged for 10 min at 2038×g
at ca. 4 ◦C, and 100 L of the supernatant was transferred to a new
96-well plate to which 200 L of water was added; the ﬁnal concen-
tration of acetic acid was 0.1% (v/v). The plate was  centrifuged for
5 min  (2038×g, ca. 4 ◦C), before transfer to the autosampler. Full
calibration lines were injected at the beginning and end of each
analytical run.
2.4. LC–MS/MS  conditions
A Shimadzu Nexera X2 modular system (Kyoto, Japan) was  cou-
pled to a Sciex triple quadrupole 6500 QTRAP mass spectrometer
(AB Sciex, Warrington, UK). The Shimadzu system comprised a SIL-
30AC autosampler, two LC-30AD pumps, a CTO-20 A column oven
and a CBM-20 A controller. The autosampler injected a 5 L aliquot
of each sample into the system. The autosampler and oven tem-
peratures were 4 ◦C and 40 ◦C, respectively. HPLC separation of
analytes and ISs was accomplished using a 2.7 m Halo C18 column
(50 x 2.1 mm ID, 90 Å, Hichrom Limited, Reading, UK, part num-
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er: 92812-402) and gradient separation. Mobile phase A consisted
f water with 0.1% v/v formic acid, and mobile phase B was  ace-
onitrile with 0.1% v/v formic acid. The ﬂow-rate was  500 L/min,
otal run time was 6.00 min, and the gradient parameters were:
.00–2.50 min  10% B, 2.51–3.75 min  50% B, 3.76–4.25 min 95% B,
nd 4.26–6.00 min  10% B. The MS  analysis was carried out in the
ow mass setting with a Turbo VTM electrospray source operated in
ositive ionisation mode. An integrated 6-port Valco diverter valve
as used to divert only the eluate containing the peaks of inter-
st into the source. Detection and quantiﬁcation were performed
sing multiple reaction monitoring (MRM,  MS/MS). A dwell time
f 9.0 msec per transition was used for all ATV analytes and corre-
ponding ISs, and 7.0 msec per transition for BSP, CLP-CA and their
Ss. Nitrogen, as nebuliser, heater, collision activated dissociation
CAD), and curtain gas (CUR), was supplied by a Genius 3031 nitro-
en generator (Peak Scientiﬁc, Inchinnan, UK). The optimised gas
ettings were: CAD ‘medium’; CUR 25.0; GS1 (nebuliser) 50.0, and;
S2 (heater) 40.0. The other general, optimised, parameters were:
urbo ionspray voltage 5500.0 V; entrance potential 10.0 V, and;
ource temperature 500 ◦C. Analyte and IS-speciﬁc MS  parameters
re listed in Table 1.
ig. 2. MS/MS  spectra of analytes.
ps = counts per second. This ﬁgure shows the MS/MS  precursor and product ion m/z  spec
recursor and product ions for each analyte are: ATV 559.3 & 440.3; 2-OH ATV 575.3 & 2
08.0  & 198.1. Biomedical Analysis 159 (2018) 272–281 275
2.5. Method validation
The developed assay was  validated for calibration curve per-
formance, selectivity, carryover, accuracy, precision, matrix effects
(MEs), stability and dilution integrity according to the European
Medicines Agency guidelines [20].
2.5.1. Selectivity
Selectivity was  tested by analysing extracted blank plasma from
six individuals, including one lipaemic and one haemolysed sample,
to investigate interference at the retention time of each compound.
Selectivity was accepted if the blank response of each individual
sample was less than 20% of the mean (n = 6) lower limit of quan-
tiﬁcation (LLOQ) response for an analyte, and less than 5% of mean
IS response for an IS.2.5.2. Carryover
Carryover into injected 25:75 acetonitrile-water, immediately
following injection of the top calibration standard (upper limit of
quantiﬁcation, ULOQ), was  assessed. Carryover was  accepted if it
tra for each analyte. The cited cps refers to the highest peak (at 100%). The selected
50.2; ATV L 541.3 & 276.2; 2-OH ATV L 557.3 & 276.2; BSP 326.2 & 116.2; CLP-CA
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Fig. 3. Representative MRM  chromatograms of blank human plasma spiked with analytes at LLOQ (I), internal standard (II), or with no spiking (III).
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phis  ﬁgure shows representative multiple reaction monitoring chromatograms of: (
ith  internal standard, and; (III) blank human plasma with no spiking (i.e. double b
 = ATV; B = 2-OH ATV; C = ATV L; D = 2-OH ATV L; E = BSP; F = CLP-CA; G = ATV-d5; H
as less than 20% of the LLOQ for an analyte, and less than 5% of IS
esponse for an IS.
.5.3. Lower limit of quantiﬁcation
The LLOQ for each analyte had a response at least 5x that of
he mean blank response, and constituted the lowest calibration
tandard.
.5.4. Accuracy and precision
To evaluate the accuracy and precision of the method, four con-
entrations for each analyte (LLOQ and low, medium and high QCs)
ere analysed in six replicates per run. Three runs were carried
ut, and each run was conducted on a separate day by a different
perator. Within run (n = 6) and between run (n = 18) accuracy and
recision were determined. Accuracy was acceptable if the calcu-k human plasma spiked with analytes at the LLOQ; (II) blank human plasma spiked
 The analyte retention times in the double blank extracts are denoted by the arrow.
H ATV-d5; I = ATV-d5 L; J = 2-OH ATV-d5 L; K = BSP-d5; L = CLP-d4 CA.
lated concentration was within 15% of the nominal concentration
for each QC, and within 20% at the LLOQ. Precision was acceptable
if the coefﬁcient of variation (CV) did not exceed 15% for each QC,
and 20% for the LLOQ.
2.5.5. Matrix effect and recovery
Matrix effect (ME) and extraction recovery (ER) were deter-
mined as described by Matuszewski et al [21]. Plasma from six
individuals including one lipaemic and one haemolysed sample
were tested at high and low QC concentrations. The MEs for each
analyte and IS were determined separately in each sample by deter-
mining the ratio of the peak area in the post-extraction spiked
plasma to the peak area in spiked 25:75 acetonitrile-water, and
the IS-normalised ME  for each analyte was calculated as the analyte
ME/IS ME.  A CV ≤ 15% for the IS-normalised ME  from the six samples
al and
w
a
s
2
t
d
2
a
w
l
l
(
(
e
w
b
b
s
i
2
s
o
T
S
AR.M. Turner et al. / Journal of Pharmaceutic
as acceptable. The ER was determined from the ratio of the peak
reas of the pre-extraction spiked plasma to the post-extraction
piked plasma.
.5.6. Stability
The stability of the analytes in solution and in plasma (bench
op, freeze-thaw, re-injection reproducibility and long term) was
etermined. Stock solution stability was assessed at three (ATV L,
-OH ATV L) or six (ATV, 2-OH ATV, BSP, CLP-CA) months storage
t ca. -20 ◦C, compared to fresh stock. Working solution stability
as determined at four (composite analytes) or seven (lactone ana-
ytes) weeks storage at ca. 4 ◦C. Six replicates of spiked plasma at
ow and high QC concentrations were used to determine bench top
four hours on the work surface at room temperature), freeze-thaw
three cycles with at least 12 h freezer storage at ca. -80 ◦C between
ach cycle), and long term (three months at ca. -80 ◦C) stability,
hich were assessed against fresh calibration standards. The sta-
ility of extracts in the autosampler tray, set at 4 ◦C, was assessed
y re-injecting calibration standards and QCs after they had been
tored there for 24 h. In all stability studies, potential acid-lactone
nterconversion of the ATV analytes was assessed..5.7. Dilution integrity
For dilution integrity, six replicates of pooled plasma were
piked with composite or lactone analytes to high concentrations
f: 800 ng/mL (ATV L), 1000 ng/mL (ATV, 2-OH ATV, 2-OH ATV L and
able 2
ummary of validation results.
Property QC 
Selectivity Analyte (% LLOQ) – 
Internal Standard (% IS) – 
Calibration curve performance Correlation coefﬁcient (r) 1 – 
Dilution integrity Accuracy (%)2 – 
Precision, CV (%) – 
Carryover Analyte (% LLOQ) – 
Internal Standard (% IS) – 
IS-normalised Matrix effect Mean (%)2 Low 
High 
Precision, CV (%) Low 
High 
Recovery Mean (%)2 Low 
High 
Precision, CV (%) Low 
High 
Within run accuracy and precision Accuracy (%)2 LLOQ 
Low 
Mediu
High 
Precision, CV (%) LLOQ 
Low 
Mediu
High 
Between run accuracy and
precision
Accuracy (%)2 LLOQ 
Low 
Mediu
High 
Precision, CV (%) LLOQ 
Low 
Mediu
High 
RT  Benchtop stability (% of nominal
concentration)
Low 114.3 
High  107.1 
Freeze-thaw stability (% of nominal
concentration)
Low 110.2 
High  103.6 
Long  term stability (% of nominal
concentration)
Low 107.5 
High  104.4 
Autosampler stability (% of
nominal concentration)
Low 91.9 
High  103.9 
bbreviations: LLOQ = lower limit of quantiﬁcation; IS = internal standard; QC = quality c
1 Average of 3 independent runs.
2 Accuracy is represented as % of nominal concentration. Biomedical Analysis 159 (2018) 272–281 277
BSP), and 30,000 ng/mL (CLP-CA). These high plasma samples were
diluted 20-fold in plasma and tested with fresh calibration lines.
Accuracy and precision (CV) of the diluted samples within 15% was
considered acceptable.
2.6. Application to patient samples
The full validated method was  applied to analyse steady-state
concentrations in plasma samples collected during the Pharmaco-
genetics of Acute Coronary Syndrome (PhACS) study, which has
been described previously [22]. Brieﬂy, PhACS was a multicentre
UK-based prospective cardiovascular observational study that ran
from 2008 to 2013 and recruited 1470 patients hospitalised with
a non-ST elevation acute coronary syndrome from 16 sites; par-
ticipants were followed up for further cardiovascular events for at
least 12 months. Blood samples were collected in EDTA-containing
vacutainers at baseline, and at a median of one month (M1) and
12 months (M12) after discharge from index hospitalisation, trans-
ported at room temperature, centrifuged at 2600 x g for 20 min  at
room temperature, and stored at -80 ◦C. We  included participants
on one or more of ATV (80 mg  or 40 mg  daily at both index hospital-
isation and M1), BSP (any dose) or CLP (75 mg  daily) with adherence
data for the drug(s) recorded at M1 (collected using the Brief Medi-
cation Questionnaire [23]) and an M1  plasma sample was  available.
In addition, a quarter of M1  analysed patients that had remained
on ATV 80 mg  daily, BSP (at the same dose between M1  and M12)
ATV 2-OH ATV ATV L 2-OH ATV L BSP CLP-CA
11.0 14.3 4.3 7.3 2.1 3.2
0.71 0.90 0.28 1.35 0.09 0.08
0.9995 0.9995 0.9982 0.9975 0.9983 0.9977
98.7 93.7 102.9 106.7 109.0 96.4
11.7 6.2 3.4 4.9 14.0 3.3
6.2 3.7 2.7 10.9 1.1 5.2
0.1 0.5 0.1 0.1 0.1 0.1
103.9 98.0 113.1 88.9 107.4 106.5
112.2 98.4 114.7 102.8 106.3 100.9
12.3 12.2 11.6 8.8 7.0 8.8
5.8 4.7 3.5 8.8 4.3 2.2
102.4 96.5 102.5 108.5 98.5 93.8
99.1 98.8 98.2 100.6 97.4 92.7
13.3 13.9 8.9 5.4 11.0 12.4
5.7 6.8 5.1 6.6 7.0 3.9
95.0 97.0 90.3 107.6 92.8 101.5
104.5 102.2 98.8 108.6 102.8 102.7
m 99.0 99.8 99.4 93.8 99.1 99.7
96.1 94.3 99.0 97.8 96.0 95.0
11.1 6.0 9.5 12.1 2.3 3.3
8.2 7.7 6.0 8.7 4.3 3.4
m 1.6 2.2 2.3 4.2 2.0 2.3
4.5 4.0 4.7 5.8 4.3 5.5
95.3 96.1 100.0 100.5 94.4 97.0
103.7 101.5 98.2 101.2 102.8 101.1
m 100.5 99.2 95.1 95.0 99.8 99.0
99.0 97.3 98.0 99.8 99.0 98.0
8.9 8.2 10.9 14.6 5.2 4.7
6.3 8.5 5.8 12.1 4.4 3.7
m 2.6 4.1 4.6 5.7 2.6 3.5
3.9 4.7 4.0 5.7 5.3 4.7
107.7 100.3 105.6 98.5 107.7
112.9 94.7 107.8 96.1 103.2
114.5 89.7 96.6 102.5 106.6
102.4 88.2 96.0 100.9 99.2
111.4 109.7 112.5 103.3 103.9
106.0 106.4 103.2 104.5 99.8
108.7 101.7 103.8 101.0 104.5
101.1 97.4 99.0 99.7 103.9
ontrol; CV = coefﬁcient of variation; RT = room temperature.
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r CLP at M12  with adherence data for the drug(s) recorded and
lasma sample available were selected for analysis of their M12
rug levels. In total, twenty 96-well plates were analysed in 10
nalytical runs (two plates/day). Each analytical run contained two
et of calibration standards and four replicates for each QC (low,
edium and high). The PhACS protocol was approved by the Liver-
ool (adult) research Ethics Committee, UK; site-speciﬁc approval
as granted at all sites involved and local informed consent was
btained from all study subjects in accordance with the Declaration
f Helsinki.
.7. Data analysis
Raw data were processed using MultiQuant
TM
Version 1.6.2
Sciex). The analyte/IS ratio of the peak area was calculated for
he six analytes for calibration, QC and patient samples. Sepa-
ate weighted least squares regression analyses were applied to
he linear (1/x for ATV, 2-OH ATV, 1/x2 for BSP, ATV L, 2-OH ATV
) and quadratic (1/x for CLP-CA) calibration lines. In the patient
tudy, concentrations below the LLOQ were excluded from further
nalysis. Patient drug concentrations are reported as the median
interquartile range, IQR) per dose. Pearson correlation analysis was
erformed to evaluate the relationship between the steady-state
easurements at M1  and M12  using log10 transformed concentra-
ions. The inﬂuence of sample storage duration (days) was  assessed
y linear regression of the M1  log10 transformed concentrations,
ith adjustment for dose carried out for all ATV analytes and BSP;
he correlation coefﬁcient (R2) relating speciﬁcally to the sam-
le storage variable, its unstandardized regression coefﬁcient (B),
nd corresponding p-value are reported. P-values are two-sided
nd p < 0.05 was considered statistically signiﬁcant. Patient ana-
yte concentrations were illustrated using R [24]; correlation and
egression analyses were performed in IBM SPSS version 22.0 (IBM
orp, Armonk, NY, USA).
. Results and discussion.1. Optimisation of LC–MS/MS  conditions
The 2.7 m Halo C18 column was selected because it provided
 symmetrical peak shape for all analytes and, in combination
able 3
ummary of analyte concentrations for each dose in plasma samples.
Analyte M1,  n Dose (mg) Samples at
M1  above
LLOQ, n (%)1
Conc. (ng/mL)
Median (IQR)
ATV 718 40 43 (97.7) 4.86 (1.92-9.53)
80  631 (93.6) 5.67 (3.19-10.98) 
2-OH ATV 40 42 (95.5) 5.85 (2.80-8.81) 
80  640 (95.0) 7.49 (4.26-12.76) 
ATV L 40 31 (70.5) 3.98 (2.51-8.90) 
80  569 (84.4) 4.94 (2.87-9.41) 
2-OH ATV L 40 42 (95.5) 4.64 (2.74-9.73) 
80  644 (95.5) 7.49 (4.39-13.22) 
BSP 736 1.25 140 (99.3) 5.67 (4.31-7.63)
2.5 316 (98.8) 10.83 (8.24-14.05) 
3.75  21 (100.0) 17.50 (12.53-23.05) 
5  167 (96.0) 23.14 (17.08-28.86) 
6.25  2 (100.0) 55.342
7.5 24 (96.0) 36.74 (27.35-45.67) 
10  49 (98.0) 43.93 (28.06-52.73) 
20  3 (100.0) 105.493
CLP-CA 811 75 792 (97.7) 736.94
(392.13-1211.11)
oncentrations below the LLOQ were excluded from the median (IQR) concentration c
erformed on log10 transformed concentrations. 1 = the LLOQ was  0.5 ng/mL for ATV, 2-O
amples; 3 = n = 3 samples; 4 = n = 1 sample. Biomedical Analysis 159 (2018) 272–281
with the mobile phase and run time (6 min) used, it provided clear
peak separation and both favourable intensity and selectivity. For
instrument tuning and MS  parameter optimisation, concentrated
standard solutions of each analyte were infused separately using
a syringe pump into the eluate from the column, prior to the MS.
During tuning, the MS/MS  parameters were systematically evalu-
ated to optimise the response for each analyte and IS. The MS/MS
spectra are shown in Fig. 2.
3.2. Optimisation of extraction procedure
A simple, rapid, reproducible and robust protein precipitation
extraction method was desired so that minimal volumes of stored
patient plasma samples could be analysed in support of a large
sparse pharmacokinetic study. A deuterated IS was used for each
analyte to aid selectivity and reproducibility. Assay recovery and
reproducibility were then optimised through a two-step extrac-
tion procedure, where the IS solution (20 L) was added to a spiked
plasma sample (50 L) and agitated, before the protein precipita-
tion solvent (180 L) was  added and the mixture brieﬂy re-agitated.
The use of acetic acid within the acetonitrile precipitation sol-
vent, to give a ﬁnal concentration of 0.1% (v/v) (lowering plasma
pH to 4–6), and maintaining the autosampler temperature at 4 ◦C
were selected to reduce lactone to acid conversion of ATV lac-
tone metabolites as previously reported [25,26]. The analyte, IS
and double blank plasma representative chromatograms in Fig. 3
collectively demonstrate minimal endogenous interferences at the
retention times of the six analytes and their deuterated IS. Overall,
only 50 L of sample was required, sample extraction within one
hour was  feasible, and 218 samples could be analysed over 24 h.
3.3. Method validation
The bioanalytical method described here met  full validation
criteria for calibration curve performance, selectivity, carryover,
accuracy, precision, MEs, stability and dilution integrity (Table 2).
The calibration curve was  validated for all analytes over the
following ranges: 0.5–125 ng/mL for ATV, 2-OH ATV, 2-OH ATV L
and BSP, 1.2–100 ng/mL for ATV L, and 15-3,750 ng/mL for CLP-CA.
The LLOQ was 0.5 ng/mL for ATV, 2-OH ATV, 2-OH ATV L and BSP,
1.2 ng/mL for ATV L and 15 ng/mL for CLP-CA. The within run and
M12, n Samples at
M12  above
LLOQ, n (%)1
Conc. (ng/mL)
Median (IQR)
M1 & M12  correlation
Pearson
correlation
p-value
173 – – – –
157 (90.7) 4.97 (2.81-8.48) 0.346 1.40 × 10−5
– – – –
163 (94.2) 7.48 (3.86 – 11.42) 0.294 1.76 × 10−4
– – – –
131 (75.7) 4.33 (2.71-7.46) 0.316 3.88 × 10−4
– – – –
165 (95.4) 6.63(4.07-9.86) 0.268 5.94 × 10−4
182 26 (96.3) 5.50 (4.28-7.05) 0.640 4.37 × 10−22
83 (100.0) 10.27 (6.78-13.67)
6 (100.0) 13.34 (10.13-18.27)
49 (98.0) 20.32 (15.50-30.68
1 (100.0) 58.74
4 (100.0) 32.38 (12.70-51.56)
10 (90.9) 53.37 (37.17 – 68.51)
1 (100.0) 167.24
205 195 (95.12) (737.58
(414.61-1124.49)
0.255 3.34 × 10−4
alculations and M1  to M12  correlation analysis. Pearson correlation analysis was
H ATV, 2-OH ATV L and BSP, 1.2 ng/mL for ATV L, and 15 ng/mL for CLP-CA; 2 = n = 3
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etween run accuracy and precision of the LLOQ and QCs for all ana-
ytes were within the accepted range. Following a 20-fold dilution,
or all analytes the accuracy was 93.7–109% and the CV 3.3–14%;
herefore, dilution up to 20 times for patient samples higher than
he ULOQ was acceptable. Analyte responses were stable in plasma
n the benchtop (four hours, room temperature), after three freeze-
◦haw cycles, after three months of storage (at ca. -80 C), and in
he autosampler (24 h, set at 4 ◦C). Moreover, analyte responses in
tored stock and working solutions were within 15% of the fresh
olution responses, which was considered acceptable.ned from PhACS patients.
Lactonization of the acid form and hydrolysis of a lactone to
the open-acid form of ATV are mediated by uridine 5′-diphospho-
glucuronosyltransferases (UGTs) [27] and paraoxonases [28],
respectively. ATV analyte acid-lactone interconversion has been
investigated extensively before [26]. In keeping with these previ-
ous ﬁndings, the interconversion of ATV to ATV L, and 2-OH ATV to
2-OH ATV L, was uniformly negligible in our assay, with an increase
in the proportion of lactone species of ≤0.3% in all stock, working
solutions, and plasma-based stability studies. The lactone metabo-
lites and particularly ATV L are more unstable [26]. However, this
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an be almost completely negated by lowering the temperature
o 4 ◦C and/or lowering the pH during extraction with acetic acid
26]. In our assay, ATV L to ATV and 2-OH ATV L to 2-OH ATV con-
ersion in stability studies was less than 5%, except for ATV L to
TV in plasma after three freeze-thaw cycles and after four hours
t room temperature. Nevertheless, sample extraction within one
our is feasible and lactone to acid conversion after one hour in
piked plasma on the benchtop was <5%. Furthermore, lactone to
cid conversion after four hours on the bench top in ice (ca. 4 ◦C)
as <1.5%. Thus, we recommend sample extraction without delay if
amples undergo extraction at room temperature, or extraction on
ce if delays are expected. Minimising the number of freeze-thaw
ycles, modestly lowering the pH during extraction and running
he autosampler at ca. 4 ◦C are all recommended.
.4. Assay application to large clinical study
The developed HPLC-MS/MS method was successfully applied
o measure analyte concentrations in 1279 samples from 1024
atients (1024 samples at M1  and 255 at M12). Included samples
ad undergone a maximum of one freeze-thaw since ﬁrst storage.
he number of patients that met  the M1  inclusion criteria for ATV,
SP and CLP-CA were 718, 736 and 811, respectively. At M12, the
umber of eligible samples analysed for ATV, BSP and CLP-CA were
73, 182 and 205 respectively. Median (IQR) analyte concentrations
re listed in Table 3 and represented graphically in Fig. 4.
Overall, we found that at least 93% of samples have analyte levels
bove the LLOQ (M1  and M12) in this ‘real world’ cohort. Speciﬁ-
ally, the proportion of samples above the LLOQ at M1  were 93.9%
or AVT, 95.0% for 2-OH AVT, 83.6% for ATV L, 95.5% for 2-OH ATV
, 98.1% for BSP and 97.7% for CLP-CA. The proportion of samples
ith ATV L levels above the LLOQ was lower than for the other
TV analytes, because of its higher LLOQ (1.2 ng/mL). However, if
ecessary the LLOQ of ATV L could be relaxed to 0.5 ng/mL for con-
istency with the other ATV analytes, which had an accuracy and
recision (CV) of 88.8% and 28.2%, respectively, to yield an equiv-
lent number of valid samples (n = 655). Some, but not all, of the
alues below the LLOQ appear related to patient self-reported non-
dherence. The highest measured concentrations were: 141 ng/mL
ATV), 94.3 ng/mL (2-OH ATV), 135 ng/mL (ATV L), 77.3 ng/mL (2-
H ATV L), 172 ng/mL (BSP), and 4921 ng/mL (CLP-CA).
The M1  plasma samples had been stored long term for a mean
f 2317 days prior to analysis. Thus, we were unable to perform a
ong term stability assessment that spanned this duration, and so
e investigated whether sample duration (in days) was  associated
ith measured analyte levels. Univariate linear regression analysis
howed no signiﬁcant associations for ATV, BSP or CLP-CA levels.
owever, sample storage duration was associated with reduced
-OH ATV (B = 1.38 × 10−4, R2 = 2.5%, p = 3.10e-05), and increased
TV L (B = 1.84 × 10−4, R2 = 4.4%, p = 1.83 × 10-7) and 2-OH ATV L
B = 1.01 × 10−4, R2 = 1.3%, p = 0.0027) responses. Whilst the inﬂu-
nce of sample duration was strongest for ATV L, it still accounted
or less than 5% of observed variability in observed concentrations,
hich was considered acceptable.
Interestingly, there were signiﬁcant correlations for all analytes
etween the M1  and M12  steady-state measurements (Table 3).
verall, these results demonstrate the utility of the assay for anal-
sis of large sample sizes; further analyses of the data are ongoing to
elate clinical and pharmacogenomic factors to these analyte levels
nd subsequent cardiovascular events.. Conclusion
We  have developed and validated a novel, sensitive, repro-
ucible and robust assay for the quantiﬁcation in human plasma
[
[ Biomedical Analysis 159 (2018) 272–281
of six analytes highly relevant to CVD, and applied this assay, to
the best of our knowledge, to one of the largest sparse pharma-
cokinetic studies undertaken to date. The assay requires a small
sample volume, incorporates a simple extraction procedure and
rapidly separates analytes; thus, it is amenable for use in large stud-
ies. Millions of patients are regularly prescribed concomitant ATV,
BSP and CLP. However, in order to advance precision medicine, it
is necessary to further parse and act on the factors associated with
interindividual drug response variability; simple and easy-to-use
multi-analyte assays, like the one reported here, will be pivotal to
this effort.
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